Antibody–drug conjugates amplify cancer immunotherapy in selected solid tumors
A review of clinical and preclinical evidence finds that antibody–drug conjugates can improve outcomes with immune checkpoint inhibitors in several ...
A review of clinical and preclinical evidence finds that antibody–drug conjugates can improve outcomes with immune checkpoint inhibitors in several ...
A comprehensive systematic review and meta-analysis has revealed that low-dose immune checkpoint inhibitors (ICIs) demonstrate comparable efficacy and safety profiles ...
A new review maps the rapid rise of NK cell immunotherapy for solid tumors and warns that its cardiovascular safety ...
Scientists at the Italian Institute of Technology in Naples have engineered CAR-T cells with a synthetic genetic switch that activates ...
MIT researchers have engineered ligand-directed lipid nanoparticles that reprogram natural killer cells into CAR-bearing cancer killers directly inside living animals, ...
A preclinical study shows that CAR-T cells engineered to secrete an Fc-fused IL-2(C125S) variant persist longer, retain mitochondrial fitness, and ...
Cancer immunotherapy is entering a new phase in which the goal is no longer simply to “release the brakes” on ...
For years, CAR-T cell therapy has stood as one of cancer medicine’s most striking successes. By removing a patient’s T ...
In recent years, the landscape of cancer therapy has been revolutionized by innovative approaches that harness the power of the ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine